Genworth Financial

GNW · NYSE

$8.97+$0.03 (+0.34%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.94

GNW analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $12.65 (+41.1% upside)

Low: $11.61
Now: $8.97
High: $13.98

Upgrades and downgrades

The latest rating actions, newest first

GNW analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Keefe, Bruyette & Woods	Oct 9, 2026	Downgrade	Outperform → Market Perform	$11.50 → $10.50	71%
Keefe, Bruyette & Woods	Sep 16, 2026	Maintains	Outperform	$12.00 → $11.50	71%
Keefe, Bruyette & Woods	Jul 13, 2026	Maintains	Outperform	$11.00 → $12.00	71%
Keefe, Bruyette & Woods	May 13, 2026	Maintains	Outperform	$10.50 → $11.00	71%
Keefe, Bruyette & Woods	Mar 26, 2026	Initiates	Outperform	$10.50	71%

The case for and against

Updated Dec 8, 2025

Bull case

Genworth Financial, a diversified insurance holding company, benefits from a favorable operating environment marked by higher interest rates, demographic trends, and technological advancements, all of which contribute to enhanced growth potential. The company’s Enact segment has achieved a significant 17% market share, with projections indicating a 2-3% annual growth in insurance in-force over the intermediate term while maintaining return on equity (ROEs) between 11-13%, aligning with industry peers. Additionally, the broader life insurance industry has shown steady improvement over the past decade, decreasing liability tail risks and expanding free cash flow, which supports a positive outlook for Genworth Financial.

Bear case

Genworth Financial has faced significant legal challenges, including an $850 million payment to AXA for pre-2005 mis-selling liabilities, which poses ongoing financial risks and uncertainty for the company. Although Genworth has reduced its leverage from $2.7 billion in 2020 to $0.8 billion and executed $590 million in buybacks since 2022, the substantial legal liabilities may detract from the potential benefits of these efforts. The outcome of the AXA lawsuit, among others, could further impact Genworth's financial stability and investor confidence, contributing to a negative outlook on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.